疫苗增强性疾病风险探讨

doi:10.19803/j.1672-8629.2021.04.09

摘要/Abstract

摘要： 目的对疫苗增强性风险进行探讨,为新型冠状病毒疫苗上市后安全性监测提供参考。方法通过检索、整理国内外关于病毒类疫苗与疫苗增强性疾病的研究成果,关注新型冠状病毒疫苗潜在的安全性问题。结果与结论 2020年新型冠状病毒引发的疫情蔓延全球,由于目前尚无针对新型冠状病毒的特效治疗药物,新型冠状病毒疫苗的研发己成为全球关注的热点。疫苗增强性疾病是疫苗研发和上市后安全性监测中普遍关注的一个问题。根据目前已有的研究成果,疫苗增强性疾病风险成为新型冠状病毒疫苗的不确定性因素,需要在今后的研究和使用中认真分析和评价。

关键词: 抗体依赖增强作用, 疫苗增强性疾病, 新型冠状病毒, 新型冠状病毒疫苗

Abstract: Vaccine Enhancement of Disease was discussed in this paper, in order to provide information for post-marketing surveillance of SARS-CoV-2 vaccines. Methods The documents and research findings about virus vaccines and vaccine enhancement of disease (VED) were collected to analyze the safety of SARS-CoV-2 vaccines. Results and Conclusion The epidemic caused by SARS-CoV-2 has been spreading globally since 2020. As no wonder drugs are currently available, vaccine development is becoming a hot topic worldwide. Due to its uncertainty, VED is one of the common concerns during vaccine development and post-marketing surveilance should be carefully assessed in the future.

Key words: antibody-dependent enhancement, vaccine enhancement of disease, SARS-CoV-2, SARS-CoV-2 vaccines

中图分类号:

R954.5

王亚丽. 疫苗增强性疾病风险探讨[J]. 中国药物警戒, 2021, 18(4): 338-340.

WANG Yali. Discuss about Vaccine Enhancement of Disease[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 338-340.

参考文献

[1] Bulut C, Kato Y.Epidemiology of COVID-19[J]. Turk J Med Sci, 2020, 21(50): 563-570.
[2] Shi Y, Wang G, Cai XP, et al.An overview of COVID-19[J]. J Zhejiang Univ Sci B. 2020, 21(5): 343-360.
[3] Kang Z, Tang M.Progress and analysis on the development of 2019-nCoV vaccine[J]. China Academic Journal Electronic Publishing House(生物医学工程学杂志).. 2020 ,37(3): 373-379.
[4] Wang Y, Yin HJ, Wang QL, et al.The common problem of COVID-19 vaccines in non-clinical research[J]. Chin J Biologicals July(中国生物制品学杂志), 2020, 33(7): 837-839.
[5] Arvin AM, Fink K, Schmid MA, et al.A perspective on potential antibody-dependent enhancement of SARS-CoV-2[J]. Nature, 2020, 13: 2538-2538.
[6] Huisman W, Martina BEE, Rimmelzwaan GF, et al.Vaccine-induced enhancement of viral infections[J]. Vaccine, 2009, 27(4): 505-512.
[7] Ulrich H, Pillat MM, Tárnok A.Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): A perspe-ctive[J]. Cytometry A, 2020, 97(7): 662-667.
[8] Halstead SB.Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner[J]. Cold Spring Harb Perspect Biol, 2018, 10(6): a030700.
[9] WHO. Dengue position paper[M/OL]. (2017-09-07) [2020-08-04] https://www.who.int/immunization/policy/position_papers/dengue/en/.(2017-09-07) [2020-08-04].
[10] Prompetchara E, Ketloy C, Palaga T.Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic[J]. Asian Pac J Allergy Immunol, 2020, 38(1): 1-9.
[11] Ma C, Su S, Wang J, et al.From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development[J]. Microbes Infect, 2020, 22(6-7): 245-253.
[12] Smatti MK, Thani AAAl, Yassine HM.Viral-induced enhanced disease illness-mark[J]. Front Microbiol. 2018, 9: 2991.
[13] Yip M S, Leung NHL, Cheung C Y, et al.Antibody-dependent infection of human macrophages by dsevere acute respiratory syndrome coronavirus[J]. Virol J, 2014, 11: 82.
[14] Hotez PJ, Corry DB, Bottazzi ME.COVID-19 vaccine design: the janus face of immune enhancement[J]. Nat Rev Immunol, 2020, 20(6): 347-348.
[15] Yip MS, Leung HL, Li PH, et al.Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS[J]. Hong Kong Med J, 2016, 22(3 Suppl 4): 25-31.
[16] Luo F, Liao FL, Wang H, et al.Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV Vaccine[J]. Virol Sin, 2018, 33(2): 201-204.
[17] Lambert PH, Ambrosino DM, Andersen SR, et al.Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines[J]. Vaccine, 2020, 38(31): 4783-4791.
[18] Zhang QT, Wang YL, Qu Y.Discussion on vaccine active surveillance in china[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(11): 673-675.